Skip to main content
    P

    Penumbra Inc (PEN)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $319.30
    -1.81 (-0.56%)

    Market Cap: $12.71B

    Last updated: Nov 06, 2026 at 4:10 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    78%(31/40)
    Avg Surprise
    +236.58%

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$1.09
    Range$1.02 - $1.20
    3 analysts
    Revenue Consensus
    $446M
    Range$438M - $450M
    4 analysts
    Period ending Mar 31, 2027
    EPS Consensus$1.40
    Range$1.33 - $1.49
    5 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$1.39+0.8%
    60d ago$1.39+0.8%
    30d ago$1.39+0.8%
    7d ago$1.41-0.6%
    Current$1.40
    Revenue Consensus
    $423M
    Range$419M - $426M
    4 analysts
    Last 12 of 40 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Mar 27EST
    		-$1.40$1.33 - $1.49--5
    0
    1
    30d
    		-
    Dec 26EST
    		-$1.09$1.02 - $1.20--3--
    Sep 26
    Reported Oct 29
    		$1.07$1.21$1.07 - $1.29-11.57%Miss7
    1
    3
    30d
    		+10.3%
    Jun 26
    Reported Jul 30
    		$0.88$1.15$1.05 - $1.27-23.48%Miss11
    0
    5
    30d
    		+2.3%
    Mar 26
    Reported May 6
    		$1.01$1.06$1.00 - $1.14-4.72%Miss10
    2
    2
    30d
    		+21.7%
    Dec 25
    Reported Feb 25
    		$1.18$1.10$0.99 - $1.24+7.27%Beat18
    4
    1
    30d
    		+21.6%
    Sep 25
    Reported Nov 5
    		$0.97$0.90$0.85 - $1.03+7.78%Beat19
    3
    14
    30d
    		+14.1%
    Jun 25
    Reported Jul 29
    		$0.86$0.82$0.71 - $0.90+4.88%Beat18
    0
    1
    30d
    		+34.4%
    Mar 25
    Reported Apr 23
    		$0.83$0.67$0.52 - $0.84+23.88%Beat18
    2
    2
    30d
    		+102.4%
    Dec 24
    Reported Feb 18
    		$0.97$0.89$0.80 - $1.08+8.54%Beat18
    2
    1
    30d
    		+27.6%
    Sep 24
    Reported Oct 30
    		$0.85$0.69$0.50 - $0.85+23.19%Beat17
    1
    0
    30d
    		+26.9%
    Jun 24
    Reported Jul 30
    		$0.64$0.56$0.51 - $0.61+14.29%Beat15
    No revisions (30d)
    		+48.8%
    Mar 24
    Reported May 7
    		$0.41$0.38$0.30 - $0.61+7.89%Beat14
    No revisions (30d)
    		+78.3%
    Dec 23
    Reported Feb 22
    		$0.76$0.70$0.57 - $0.87+8.57%Beat14
    1
    0
    30d
    		+375.0%

    Key Metrics

    Valuation
    P/E Ratio77.13EV/EBITDA58.88x
    Price/FCF62.81xFCF Yield1.59%
    Profitability
    Profit Margin10.10%Operating Margin12.40%
    ROE10.70%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio5.89xQuick Ratio3.92x
    Trading Statistics
    Beta0.69Avg Volume406.87K
    52-Week High$362.4152-Week Low$262.94

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$321.27
    SMA 20$321.78
    SMA 50$320.24
    SMA 200$326.64
    EMA 10$321.05
    EMA 20$321.10
    EMA 50$320.89
    EMA 200$317.60

    MACD

    Line: 0.10Signal: 0.42Hist: -0.32

    ADX

    ADX: 23.2+DI: 16.2-DI: 25.5

    Aroon & PSAR

    Aroon Up64.0
    Aroon Down12.0
    PSAR$316.52

    Bollinger Bands

    Upper Band$325.93
    Lower Band$317.62
    %B Position258%(Upper)
    Band Width0.20

    RSI (14-Day)

    Neutral
    46.0

    Momentum Oscillators

    Stoch %K49.9
    Stoch %D51.9
    Williams %R-68.0
    ROC (10d)-1.6%
    Momentum-5.09
    CCI (20d)-88.4
    MFI (14d)50.7

    Volatility Measures

    ATR (14d)$2.73(0.9%)
    StdDev (20d)2.08
    Hist Vol10.7%(Low)

    Volume Flow

    VWAP$319.51
    OBV11.7M
    AD Line-14.1M
    CMF (20d)0.075

    Volume Metrics

    Avg Vol (20d)400.8K
    Vol Ratio0.8x
    VWMA (20d)$321.67

    Pivot Points

    R3$328.30
    R2$326.53
    R1$323.82
    Pivot Point$322.05
    S1$319.34
    S2$317.57
    S3$314.86

    Advanced Oscillators

    TSI1.26
    Ultimate Osc47.3
    KST8.12

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$410.14M$390.05M$374.76M$385.38M$354.69M$339.45M$324.14M$315.52M$301.04M$299.40M$278.65M$284.68M
    Cost of Revenue$129.84M$125.10M$121.35M$123.26M$114.27M$115.44M$108.26M$104.80M$100.73M$136.57M$97.52M$97.69M
    Gross Profit$280.30M$264.94M$253.41M$262.13M$240.42M$224.01M$215.88M$210.72M$200.31M$162.83M$181.14M$186.99M
    Operating Expenses$229.56M$223.91M$215.18M$202.90M$191.58M$183.18M$175.53M$167.95M$164.94M$243.79M$169.04M$151.96M
    R&D$25.36M$25.40M$22.38M$21.79M$22.68M$23.22M$22.08M$20.01M$25.20M$24.94M$24.63M$21.94M
    SG&A$204.20M$198.51M$192.79M$181.10M$168.90M$159.96M$153.46M$147.94M$139.74M$141.90M$144.41M$130.02M
    Operating Income$50.74M$41.04M$38.23M$59.23M$48.84M$40.83M$40.35M$42.77M$35.36M$-80,961,000$12.10M$35.03M
    Interest Income$5.58M$5.15M$3.45M$0$3.49M$4.48M$3.51M$0$4.41M$3.09M$2.52M$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$56.32M$46.19M$41.69M$63.63M$52.33M$45.31M$43.86M$44.34M$39.78M$-77,874,000$14.63M$38.16M
    Income Tax Expense$14.04M$11.38M$9.10M$16.33M$6.47M$0$4.63M$10.66M$10.25M$-17,674,000$3.62M$-16,060,000
    Net Income$42.28M$34.81M$32.58M$47.34M$45.85M$45.27M$39.22M$33.68M$29.53M$-60,200,000$11.00M$54.22M
    EBITDA$56.20M$46.65M$42.81M$63.69M$51.33M$46.34M$45.37M$47.16M$39.51M$-73,314,000$19.62M$42.07M
    EBIT$50.74M$41.04M$38.23M$59.23M$48.84M$40.83M$40.35M$42.77M$35.36M$-80,961,000$12.10M$35.03M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PEN

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    1
    Avg Remaining Term
    N/A

    Recent Awards

    Award IDAgencyObligatedStart
    36C24226P0817Department of Veterans AffairsDepartment of Veterans Affairs$0Jul 16, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Penumbra revenue up 15.6% to USD 410.1M in Q3 2026

    Penumbra, Inc. reported strong financial results for the third quarter ended September 30, 2026, with revenue increasing by 15.6% to $410.1 million compared to the same period in 2025. This growth was driven by...

    Medical Buyer•10/31/26•Neutral

    Revenue rises 15.6% at Penumbra (PEN), but quarterly profit falls.

    Penumbra, Inc. reported a 15.6% increase in third-quarter 2026 revenue, reaching $410.1 million, driven by strong growth in global thrombectomy and embolization and access revenues. Despite the revenue growth...

    Stock Titan•10/30/26•Neutral

    Penumbra, Inc. (PEN) Misses Q3 EPS by 13c

    Penumbra, Inc. (PEN) reported its Q3 earnings, with an EPS of $1.07, missing the analyst estimate of $1.20 by $0.13. Despite the EPS miss, the company's revenue for the quarter came in at $410.14 million...

    StreetInsider•10/30/26•Bearish

    Penumbra Earnings: Solid Quarterly Results as Firm Awaits Closure of Boston Acquisition

    Penumbra reported strong third-quarter results with double-digit revenue growth across both its thrombectomy and embolization/access segments. Neurovascular sales also saw significant growth. The company is currently...

    Morningstar•10/30/26•Bullish

    Press Release: Penumbra, Inc. Reports Third Quarter 2026 Financial Results

    Penumbra, Inc. reported its financial results for the third quarter of 2026. The report provides detailed financial figures and performance metrics for the period. This press release is a standard announcement detailing...

    富途牛牛•10/30/26•Neutral

    PEN Valuation and Fair Value

    P/E
    77.1x
    Forward P/E
    55.9x
    EV/EBITDA
    58.9x
    P/FCF
    62.8x
    PEG
    3.6x
    P/B
    7.9x
    See GNG's fair value

    PEN Profitability: Margins, ROIC and FCF

    Gross margin
    68.0%
    Operating margin
    12.4%
    Net margin
    10.1%
    ROE
    10.7%
    FCF margin
    12.8%
    FCF yield
    1.6%

    PEN Competitors

    CompanyTicker
    Tempus AI, Inc. Class A Common StockTEM
    Dr. Reddy’s Laboratories Ltd ADRRDY
    Summit Therapeutics PLCSMMT
    DaVita HealthCare Partners IncDVA
    BrightSpring Health Services, Inc. Common StockBTSG
    Fresenius Medical Care CorporationFMS
    Baxter International IncBAX
    Elanco Animal HealthELAN

    Sector: Healthcare

    PEN Analyst Ratings

    Consensus
    Hold
    Analysts
    17
    Strong Buy
    1
    Buy
    2
    Hold
    14
    Sell
    0
    Strong Sell
    0

    PEN Bull Case vs Bear Case

    Bull case

    • PEN grew quarterly revenue 15.6% year over year.

    Bear case

    • PEN trades at 77.1x trailing earnings.

    PEN Earnings: Beat Rate and Next Report

    Beat rate
    5 of 8 quarters (62.5%)
    Average surprise
    1.6%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $1.09

    PEN Earnings Call

    The latest PEN earnings call transcript on file is labeled 2025Q3.

    Read the 2025Q3 transcript

    PEN ETF Holders

    GNG tracks 20 ETFs that hold PEN. The largest weights:

    1. NYLIM Merger Arbitrage ETF (MNA), 2.30% of the fund
    2. iShares U.S. Medical Devices ETF (IHI), 1.68% of the fund
    3. State Street SPDR S&P Health Care Equipment ETF (XHE), 1.53% of the fund
    4. BlackRock Health Sciences Trust (BME), 0.72% of the fund
    5. AGF U.S. Market Neutral Anti-Beta Fund (BTAL), 0.40% of the fund
    Open the ETF Stock Exposure tool for PEN

    See insider activity

    Frequently Asked Questions About PEN

    Does PEN pay dividends?

    Penumbra Inc (PEN) does not currently pay a regular dividend.

    What is PEN's P/E ratio?

    Penumbra Inc has a price-to-earnings (P/E) ratio of 77.13.

    What is PEN's market cap?

    Penumbra Inc (PEN) has a market capitalization of $12.71B with a current stock price of $319.30.

    Related stocks

    Sector: Healthcare

    All stocks starting with P

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In